ESCALA Therapeutics, Inc.

a majority-owned subsidiary of Fortress Biotech, Inc., is a development stage company focused on the clinical development and commercialization of therapies for orphan disorders.

We are currently developing N-acetyl-D-mannosamine (ManNAc) for the potential treatment of GNE myopathy and primary podocyte (glomerular) disorders in collaboration with NIH researchers.